Literature DB >> 30294662

Human Papilloma Virus Vaccine Awareness and Vaccination History in Patients Attending STI Clinics in Lagos and Ibadan, Nigeria.

A O Faneye1, A A Adeiga2, O B Awoderu2, A S Fayemiwo3.   

Abstract

HPV is one of the most common causes of sexually transmitted disease in both men and women worldwide. It is transmitted through vaginal, anal, and oral sex. This study provided information on the Human Papilloma Virus (HPV) vaccine awareness and vaccination history in relation to the level of antibodies to (HPV) in the population at risk in Nigeria. Patients attending STI clinics at Lagos and Ibadan were recruited and informed consent was obtained from all the participants. Using semi structured questionnaire, vaccination history, demography and past experiences of the patients were obtained. Whole blood samples were obtained and the sera screened for specific antibodies to HPV using ELISA test kits for determination of IgG to HPV by DIA PRO Diagnostic Bioprobes Milano-Italy according to the manufacturer's instruction. Of the170 samples analysed 50 (29.4%) samples were positive for HPV. Thirty (17.6%) were from females and 20 (11.7%) of them were males. Thirty-five (35%) of the 100 women participants were aware of HPV vaccine. 15(15%) women did not take the vaccine because they did not know where to get it while 20 (20%) of them could not afford it. It was also noted that there is higher prevalence among the middle-aged women. A high prevalence of HPV antibodies was observed in the study yet none of the participants had received the HPV vaccine thus the antibodies may be from infection. Implication is that the 30 women who tested positive for the HPV antibodies may be at risk of cervical cancer.

Entities:  

Keywords:  Adolescents; Confirmatory factor analysis; Structural analyses; WHO quality of life BREF

Year:  2018        PMID: 30294662      PMCID: PMC6169802     

Source DB:  PubMed          Journal:  Arch Basic Appl Med        ISSN: 2360-9680


  11 in total

1.  TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk.

Authors:  Gisela Barbisan; Luis Orlando Pérez; Anahí Contreras; Carlos Daniel Golijow
Journal:  Tumour Biol       Date:  2012-05-17

2.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

3.  Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.

Authors:  Thomas Hiller; Sven Poppelreuther; Frank Stubenrauch; Thomas Iftner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

4.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

5.  Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner.

Authors:  Sun Gwan Hwang; Daeyoup Lee; Jiyun Kim; Taegun Seo; Joonho Choe
Journal:  J Biol Chem       Date:  2001-11-16       Impact factor: 5.157

6.  Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Authors:  Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

7.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 8.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.

Authors:  Silvia de Sanjosé; Mireia Diaz; Xavier Castellsagué; Gary Clifford; Laia Bruni; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Infect Dis       Date:  2007-07       Impact factor: 25.071

Review 9.  Classification of papillomaviruses.

Authors:  Ethel-Michele de Villiers; Claude Fauquet; Thomas R Broker; Hans-Ulrich Bernard; Harald zur Hausen
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

10.  Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.

Authors:  S S Wang; M Schiffman; T S Shields; R Herrero; A Hildesheim; M C Bratti; M E Sherman; A C Rodriguez; P E Castle; J Morales; M Alfaro; T Wright; S Chen; B Clayman; R D Burk; R P Viscidi
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  1 in total

Review 1.  Cervical Cancer and Human Papillomavirus Vaccine Knowledge, Utilisation, Prevention Educational Interventions and Policy Response in Nigeria: A Scoping Review.

Authors:  Yetunde O John-Akinola; Chizoma M Ndikom; Mojisola M Oluwasanu; Temitayo Adebisi; Oluwaponmile Odukoya
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.